Logo

American Heart Association

  13
  0


Final ID: MP2658

Outcomes of Myocardial Recovery in Pediatric Patients Supported with Ventricular Assist Devices: A Multi-Center Analysis of the UNOS Registry

Abstract Body (Do not enter title and authors here): Background: Myocardial recovery on durable left ventricular assist device (LVAD) support is a rare but important and understudied outcome. The incidence and outcomes of LVAD explant for recovery in children listed for heart transplant (HT) are not well understood.

Objective: To describe the incidence and outcomes of LVAD explant for myocardial recovery in children listed for HT.

Methods: Using the United Network of Organ Sharing registry, this retrospective cohort study included pediatric patients (<18 years) who received a durable LVAD and were listed for HT between 2011 and 2023. Patients were tracked until death, HT, or explant for myocardial recovery. The cohort undergoing explant were followed for major adverse events (death, delisting due to clinical deterioration, transplantation, or re-implant of an LVAD) through December 31, 2024.

Results: Among 1,894 pediatric LVAD recipients, explant for recovery was observed in 57 patients (3.0%) from 33 centers (42% of implanting hospitals). Median time to explant was 54 days (IQR, 16-113). Compared to those not explanted for recovery, these patients were younger (median age 1 year [IQR 0-1] vs. 5 [0-12], p=<0.001) and more often supported with inotropes (56.1% vs. 38.9%, p=0.02), mechanical ventilation (45.6% vs. 20.7%, p<0.001), and ECMO (14% vs. 5.9%, p=0.04) at listing. Freedom from major adverse events was 74% at 1 year with the greatest risk within the first 60 days of explant. One-year post-explant mortality was 7.0% (95% CI, 2.2-15.7%). (Fig 1)

Conclusions: LVAD explant for myocardial recovery is rare in pediatric patients listed for HT and is concentrated in fewer than half of implanting centers. However, 74% of explanted patients remained free of a major adverse event, and 1 year survival after explant for recovery was 93%. These data highlight the potential for recovery and underscore the need to identify predictors of successful explant to broaden this therapeutic option to additional patients.
  • Wooster, Luke  ( Children's Hospital of Philadelphia , Philadelphia , Pennsylvania , United States )
  • Montgomery, Catherine  ( Children's Hospital of Philadelphia , Philadelphia , Pennsylvania , United States )
  • Rossano, Joseph  ( Children's Hospital of Philadelphia , Philadelphia , Pennsylvania , United States )
  • Edelson, Jonathan  ( Children's Hospital of Philadelphia , Philadelphia , Pennsylvania , United States )
  • O'connor, Matthew  ( Children's Hospital of Philadelphia , Philadelphia , Pennsylvania , United States )
  • Zhang, Xuemei  ( Children's Hospital of Philadelphia , Philadelphia , Pennsylvania , United States )
  • Ahmed, Humera  ( Children's Hospital of Philadelphia , Philadelphia , Pennsylvania , United States )
  • Edwards, Jonathan  ( Children's Hospital of Philadelphia , Philadelphia , Pennsylvania , United States )
  • Lin, Kimberly  ( Children's Hospital of Philadelphia , Philadelphia , Pennsylvania , United States )
  • Wittlieb-weber, Carol  ( Children's Hospital of Philadelphia , Philadelphia , Pennsylvania , United States )
  • Devlin, Paul  ( Children's Hospital of Philadelphia , Philadelphia , Pennsylvania , United States )
  • Gardner, Monique  ( Children's Hospital of Philadelphia , Philadelphia , Pennsylvania , United States )
  • Author Disclosures:
    Luke Wooster: DO NOT have relevant financial relationships | Catherine Montgomery: No Answer | Joseph Rossano: DO have relevant financial relationships ; Consultant:AskBIo:Active (exists now) ; Consultant:CRI Biotech:Active (exists now) ; Consultant:Bayer:Active (exists now) ; Consultant:Bristol Myers Squibb:Active (exists now) ; Consultant:Astellas:Active (exists now) | Jonathan Edelson: DO have relevant financial relationships ; Consultant:abiomed :Past (completed) ; Speaker:medtronic:Past (completed) | Matthew O'Connor: DO NOT have relevant financial relationships | Xuemei zhang: DO NOT have relevant financial relationships | Humera Ahmed: DO NOT have relevant financial relationships | Jonathan Edwards: DO NOT have relevant financial relationships | Kimberly Lin: DO have relevant financial relationships ; Consultant:Cytokinetics:Active (exists now) | Carol Wittlieb-Weber: DO have relevant financial relationships ; Consultant:Pfizer:Past (completed) ; Consultant:Sarepta:Past (completed) | Paul Devlin: No Answer | Monique Gardner: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Advancing Research in Advanced Heart Failure

Monday, 11/10/2025 , 12:15PM - 01:30PM

Moderated Digital Poster Session

More abstracts on this topic:
An Unusual Case of Listeria LVAD Infection Complicated by Intracranial Catastrophe

Zviman Julieann, Mouradjian Mallory, Rovelli Richard, Leventhal Sarah, Ananthram Manjula, Ramani Gautam, Jones Niya, Griffith Bartley, Dees Lynn, Nevin Amanda, Crowell Leigha, Soares Cullen, Amoroso Anthony

A Comprehensive Study on Machine Learning Models Combining with Oversampling for One-year Persistent Coronary Artery Aneurysm in Kawasaki Disease

Liang Kaizhi, Pang Yusheng, Su Danyan

More abstracts from these authors:
Greater Neighborhood Resources Predict Reduced In-Hospital Mortality for Children with Heart Failure

Markiewitz Nathan, Rossano Joseph, Edelson Jonathan, O'connor Matthew, Liu Hongyan, Penney Christopher, Ludomirsky Avital, Ahmed Humera, Edwards Jonathan, Lin Kimberly, Wittlieb-weber Carol

Obese adolescents supported with VADs have inferior post-transplant outcomes

Berger Justin, Wittlieb-weber Carol, Edwards Jonathan, Lin Kimberly, Joong Anna, Maeda Katsuhide, Edelson Jonathan, Mejia Erika, Sanderlin Rachel, Zhang Xuemei, Mavroudis Constantine, O'connor Matthew, Dewitt Aaron, Ahmed Humera, Rossano Joseph

You have to be authorized to contact abstract author. Please, Login
Not Available